Xtant Medical Holdings Inc ( (XTNT) ) has released its Q3 earnings. Here is a breakdown of the information Xtant Medical Holdings Inc presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Xtant Medical Holdings Inc. is a global medical technology company that specializes in developing and commercializing orthobiologics and spinal implant systems for complex spinal surgeries. In its latest earnings report for the third quarter of 2024, Xtant Medical reported a revenue increase of 12% to $27.9 million compared to the same period last year, with a year-to-date growth of 36%. Despite this revenue growth, the company experienced a net loss of $5.0 million, a significant change from a net income of $9.2 million in the previous year, which was influenced by a one-time gain from an acquisition. Notably, Xtant Medical launched two new products, OsteoVive+ and Cortera Posterior Fixation System, which are expected to drive future sales. The company maintained a gross margin of 58.4%, down from 61.3% last year, due to decreased production throughput. With a reaffirmed full-year revenue guidance of $116 to $120 million, representing an annual growth of 27% to 31%, Xtant Medical remains optimistic about its organic growth potential, driven by its strong product lineup and operational execution.
